Browse News

Found 54,489 articles

• 

  Researchers Develop CRISPR Mechanism to Edit Multiple DNA Sites at Once

  5/20/2022

  Rice University researchers used the foundation of CRISPR/Cas9 technology and developed “drive-and-process” arrays, or DAP for short.

• AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease

  5/20/2022

  AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ABBV-951 (foscarbidopa/foslevodopa) for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD).

• Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

  5/20/2022

  The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.

• FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

  5/20/2022

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE) aged 12 years and older, weighing at least 40 kg.

• Novel Immunotherapy Developed by City of Hope Could Provide New Treatment Model for SARS-CoV-2 Patients

  5/20/2022

  City of Hope researchers have engineered an immunotherapy using natural killer cells with a specific molecule that can target the SARS-CoV-2 virus’ spike protein, providing a novel therapeutic pathway for the treatment of COVID-19 and other infections that include the spike protein, according to a study published in Nature Communications.

• Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress

  5/20/2022

  Vera Therapeutics, Inc. (Nasdaq: VERA), today announced new clinical data for its lead product candidate, atacicept, from the Phase 2a JANUS trial in patients with IgA nephropathy (IgAN) and first-time results from a post-hoc analysis of the Phase 2 APRIL-SLE study in patients with systemic lupus erythematosus (SLE).

• Xoran Technologies Completes Phase 1 for Mobile Lung CT Grant from National Heart, Lung, and Blood Institute (NHLBI)

  5/20/2022

  Today, Xoran Technologies® announced they have completed Phase 1 for their NHLBI grant for mobile lung CT.

• Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal

  5/20/2022

  Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal.

• Trinity Biotech Announces CE Mark of its 10-Minute Covid-19 Antigen Test

  5/20/2022

  Trinity Biotech plc (Nasdaq: TRIB) has achieved a CE Mark for its 10-minute Covid-19 antigen test.

• ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy

  5/20/2022

  ClearPoint Neuro, Inc. today congratulates partner PTC Therapeutics for receiving a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending its gene therapy treatment Upstaza™ (eladocagene exuparvovec),

• TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®

  5/20/2022

  TherapeuticsMD, Inc. today announced the FDA’s approval of a supplemental New Drug Application (sNDA) for ANNOVERA.

• ASLAN Pharmaceuticals Presents Late-Breaking Poster on Eblasakimab and Neuronal Itch Mechanisms at the 2022 Society for Investigative Dermatology Annual Meeting

  5/20/2022

  ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the presentation of a poster highlighting new data and insights related to neuronal itch mechanisms through eblasakimab’s targeting of IL-13Rα1 at the Society for Investigative Dermatology (SID) Annual Meeting.

• CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

  5/20/2022

  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for OLUMIANT® (baricitinib) for the treatment of adults with severe alopecia areata (AA).

• ZBP1 links interferon treatment and dangerous inflammatory cell death during COVID-19

  5/20/2022

  Scientists from St. Jude Children's Research Hospital have shown that the innate immune sensor, ZBP1, and its associated inflammatory cell death pathway, PANoptosis, are major contributors to the negative effects of interferon treatment and high interferon levels in some COVID-19 patients.

• Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection

  5/20/2022

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection.

• Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory Teams

  5/20/2022

  Tentarix Biotherapeutics LP, a biotechnology company developing first-in-class targeted, conditional antibody-based multifunctional biotherapies, today announced the formation of a Scientific Advisory Board (SAB) and appointments to its Board of Directors and leadership team.

• Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

  5/20/2022

  Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the European Commission approve Zokinvy.

• Nanomix Receives CE Mark for its eLab COVID-19 Rapid Point-of-Care Antigen Panel

  5/20/2022

  Nanomix Corporation (OTCBB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced that it has received the CE mark for its eLab COVID-19 rapid antigen test.

• Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

  5/20/2022

  Karyopharm Therapeutics Inc. (Nasdaq:KPTI), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of NEXPOVIO® (selinexor).

• LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

  5/20/2022

  LumiraDx Limited, a next-generation point of care diagnostics company, announced that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing by the World Health Organization in their latest response effort to combat COVID-19.